Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was down 19.4% on Thursday . The stock traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares were traded during trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The business has a 50-day moving average of C$0.20 and a 200-day moving average of C$0.12. The company has a market capitalization of C$25.50 million, a P/E ratio of -5.10 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Calculate Return on Investment (ROI)
- DuPont’s Electronics Spinoff: The Start of Something Big
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- Dividend Payout Ratio Calculator
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
